
## Henry J Pownall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1634999/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 145-154.	13.9	2,294
2	Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2012, 308, 2489.	3.8	571
3	Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 913-921.	5.5	473
4	[1] Introduction to the plasma lipoproteins. Methods in Enzymology, 1986, 128, 3-41.	0.4	313
5	Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia. Circulation, 1996, 93, 1334-1338.	1.6	256
6	Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. Journal of Lipid Research, 2002, 43, 1170-1180.	2.0	253
7	Kinetics of lipid-protein interactions: interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. Biochemistry, 1978, 17, 1183-1188.	1.2	226
8	Transbilayer diffusion of phospholipids: dependence on headgroup structure and acyl chain length. Biochimica Et Biophysica Acta - Biomembranes, 1988, 938, 155-166.	1.4	215
9	Choline Deficiency Causes Reversible Hepatic Abnormalities in Patients Receiving Parenteral Nutrition: Proof of a Human Choline Requirement: A Placeboâ€Controlled Trial. Journal of Parenteral and Enteral Nutrition, 2001, 25, 260-268.	1.3	203
10	Mechanism and kinetics of transfer of a fluorescent fatty acid between single-walled phosphatidylcholine vesicles. Biochemistry, 1980, 19, 108-116.	1.2	198
11	Soluble Cell Adhesion Molecules in Hypertriglyceridemia and Potential Significance on Monocyte Adhesion. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 723-731.	1.1	196
12	Impact of Intensive Lifestyle Intervention on Depression and Health-Related Quality of Life in Type 2 Diabetes: The Look AHEAD Trial. Diabetes Care, 2014, 37, 1544-1553.	4.3	178
13	Hyperhomocysteinemia accelerates atherosclerosis in cystathionine β-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood, 2003, 101, 3901-3907.	0.6	172
14	Troglitazone Antagonizes Tumor Necrosis Factor-α-induced Reprogramming of Adipocyte Gene Expression by Inhibiting the Transcriptional Regulatory Functions of NF-κB. Journal of Biological Chemistry, 2003, 278, 28181-28192.	1.6	168
15	Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis, 1999, 143, 285-297.	0.4	161
16	Low-Density Lipoprotein in Hypercholesterolemic Human Plasma Induces Vascular Endothelial Cell Apoptosis by Inhibiting Fibroblast Growth Factor 2 Transcription. Circulation, 2003, 107, 2102-2108.	1.6	147
17	Viscosity of the hydrocarbon region of micelles. Measurement by excimer fluorescence. Journal of the American Chemical Society, 1973, 95, 3136-3140.	6.6	144
18	Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes. Diabetes Care, 2014, 37, 2548-2556.	4.3	144

#	Article	IF	CITATIONS
19	Estrogen: An Emerging Regulator of Insulin Action and Mitochondrial Function. Journal of Diabetes Research, 2015, 2015, 1-9.	1.0	134
20	Phase transitions in bilamellar vesicles. Measurements by pyrene excimer fluorescence and effect on transacylation by lecithin-cholesterol acyltransferase. Biochemistry, 1974, 13, 2828-2836.	1.2	127
21	Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nature Chemical Biology, 2012, 8, 342-349.	3.9	123
22	Metabolic basis of HIV-lipodystrophy syndrome. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E332-E337.	1.8	119
23	Kinetics and mechanism of the spontaneous transfer of fluorescent phosphatidylcholines between apolipoprotein-phospholipid recombinants. Biochemistry, 1982, 21, 3630-3636.	1.2	116
24	EFFECT OF SIROLIMUS ON THE METABOLISM OF ApoB100- CONTAINING LIPOPROTEINS IN RENAL TRANSPLANT PATIENTS1. Transplantation, 2001, 72, 1244-1250.	0.5	114
25	Kinetics of lipid-protein interactions: effect of cholesterol on the association of human plasma high-density apolipoprotein A-I with Lalphadimyristoylphosphatidylcholine. Biochemistry, 1979, 18, 574-579.	1.2	112
26	Molecular and Macromolecular Specificity of Human Plasma Phospholipid Transfer Proteinâ€. Biochemistry, 1997, 36, 3645-3653.	1.2	109
27	Reconstituted low density lipoprotein: A vehicle for the delivery of hydrophobic fluorescent probes to cells. Journal of Supramolecular Structure, 1979, 10, 467-478.	2.3	104
28	Interaction of vitamin E with saturated phospholipid bilayers. Biochemical and Biophysical Research Communications, 1982, 106, 842-847.	1.0	104
29	Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy. Journal of Lipid Research, 2011, 52, 175-184.	2.0	101
30	Isolation, Characterization, and Functional Assessment of Oxidatively Modified Subfractions of Circulating Low-Density Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1083-1090.	1.1	98
31	Shear-induced Disulfide Bond Formation Regulates Adhesion Activity of von Willebrand Factor. Journal of Biological Chemistry, 2007, 282, 35604-35611.	1.6	97
32	Transport of biological lipophiles: effect of lipophile structure. Journal of the American Chemical Society, 1983, 105, 2440-2445.	6.6	96
33	Measurement and prediction of the rates of spontaneous transfer of phospholipids between plasma lipoproteins. Lipids and Lipid Metabolism, 1984, 794, 274-280.	2.6	92
34	Absorption and emission spectra of aromatic ketones and their medium dependence. Excited states of xanthone. Journal of the American Chemical Society, 1971, 93, 6429-6436.	6.6	91
35	Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. Diabetes Care, 2016, 39, 1345-1355.	4.3	91
36	High-density lipoproteins, reverse cholesterol transport and atherogenesis. Nature Reviews Cardiology, 2021, 18, 712-723.	6.1	91

#	Article	IF	CITATIONS
37	Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. Scientific Reports, 2017, 7, 44624.	1.6	76
38	Thermodynamics of lipid-protein interactions: interaction of apolipoprotein A-II from human plasma high-density lipoproteins with dimyristoylphosphatidylcholine. Biochemistry, 1981, 20, 1575-1584.	1.2	72
39	Kinetics and mechanism of association of human plasma apolipoproteins with dimyristoylphosphatidylcholine: effect of protein structure and lipid clusters in reaction rates. Biochemistry, 1981, 20, 6630-6635.	1.2	66
40	Interfacial properties of model membranes and plasma lipoproteins containing ether lipids. Biochemistry, 1985, 24, 6973-6978.	1.2	65
41	Model of human low-density lipoprotein and bound receptor based on CryoEM. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1059-1064.	3.3	65
42	Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of â€~systemic steatosis'. Current Opinion in Lipidology, 2004, 15, 59-67.	1.2	64
43	The Polar Nature of 7-Ketocholesterol Determines Its Location within Membrane Domains and the Kinetics of Membrane Microsolubilization by Apolipoprotein A-I. Biochemistry, 2005, 44, 10423-10433.	1.2	64
44	Structures of Biologically Active Oxysterols Determine Their Differential Effects on Phospholipid Membranes. Biochemistry, 2006, 45, 10747-10758.	1.2	64
45	Effect of saturated and polyunsaturated fat diets on the composition and structure of human low density lipoproteins. Atherosclerosis, 1980, 36, 299-314.	0.4	63
46	Somatic Editing of <i>Ldlr</i> With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1997-2006.	1.1	63
47	Pyrene-labeled lipids: versatile probes of membrane dynamics in vitro and in living cells. Chemistry and Physics of Lipids, 1989, 50, 191-211.	1.5	62
48	The calcium uptake of the rat heart sarcoplasmic reticulum is altered by dietary lipid. Journal of Membrane Biology, 1993, 131, 35-42.	1.0	60
49	Serum lipoprotein structure: resonance energy transfer localization of fluorescent lipid probes. Biochemistry, 1980, 19, 1294-1301.	1.2	59
50	Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment. Neurology, 2017, 88, 2026-2035.	1.5	59
51	Effect of Moderate Alcohol Consumption on Hypertriglyceridemia. Archives of Internal Medicine, 1999, 159, 981.	4.3	58
52	The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial. Journal of Bone and Mineral Research, 2017, 32, 2278-2287.	3.1	57
53	Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: The look AHEAD study. Obesity, 2015, 23, 565-572.	1.5	55
54	Lipid binding by fragments of apolipoprotein C-III-1 obtained by thrombin cleavage. Biochemistry, 1977, 16, 5427-5431.	1.2	54

#	Article	IF	CITATIONS
55	Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A2. Journal of Lipid Research, 2007, 48, 348-357.	2.0	54
56	Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of "Heart Positive,―a Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2236-2247.	1.8	53
57	Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. American Journal of Clinical Nutrition, 2005, 81, 1405-1410.	2.2	49
58	AIBP Limits Angiogenesis Through Î <sup>3</sup> -Secretase-Mediated Upregulation of Notch Signaling. Circulation Research, 2017, 120, 1727-1739.	2.0	49
59	Cholesterol is a determinant of the structures of discoidal high density lipoproteins formed by the solubilization of phospholipid membranes by apolipoprotein A-I. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 245-253.	1.2	48
60	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity, 2020, 28, 1678-1686.	1.5	47
61	Speciation of Human Plasma High-Density Lipoprotein (HDL):  HDL Stability and Apolipoprotein A-I Partitioning. Biochemistry, 2007, 46, 7449-7459.	1.2	45
62	Action of lecithin:Cholesterol acyltransferase on model lipoproteins. Lipids and Lipid Metabolism, 1982, 713, 494-503.	2.6	44
63	Comparative specificity of plasma lecithin: Cholesterol acyltransferase from ten animal species. Lipids, 1991, 26, 416-420.	0.7	43
64	Structure of Human Apolipoprotein D: Locations of the Intermolecular and Intramolecular Disulfide Links. Biochemistry, 1994, 33, 12451-12455.	1.2	43
65	Lipoprotein-apoprotein exchange in aqueous systems: Relevance to the occurrence of APOA-I and APOC proteins in a common particle. Biochemical and Biophysical Research Communications, 1978, 85, 408-414.	1.0	42
66	Spontaneous phospholipid transfer: development of a quantitative model. Biochemistry, 1991, 30, 5696-5700.	1.2	42
67	Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. Journal of Lipid Research, 2010, 51, 297-308.	2.0	42
68	Kinetics of spontaneous and plasma-stimulated sphingomyelin transfer. Lipids and Lipid Metabolism, 1982, 712, 169-176.	2.6	41
69	Serum Opacity Factor Unmasks Human Plasma High-Density Lipoprotein Instability via Selective Delipidation and Apolipoprotein A-I Desorption. Biochemistry, 2007, 46, 12968-12978.	1.2	41
70	Isolation and specificity of rat lecithin : Cholesterol acyltransferase: Comparison with the human enzyme using reassembled high-density lipoproteins containing ether analogs of phosphatidylcholine. Lipids and Lipid Metabolism, 1985, 833, 456-462.	2.6	40
71	Physical properties of lipid-protein complexes formed by the interaction of dimyristoylphosphatidylcholine and human high-density apolipoprotein A-II. Biochemistry, 1981, 20, 1569-1574.	1.2	39
72	Electronegative LDLs from familial hypercholesterolemic patients are physicochemically heterogeneous but uniformly proapoptotic. Journal of Lipid Research, 2007, 48, 177-184.	2.0	39

#	Article	IF	CITATIONS
73	Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1552-1559.	1.7	39
74	Lateral distribution of phospholipid and cholesterol in apolipoprotein A-I recombinants. Biochemistry, 1985, 24, 7110-7116.	1.2	38
75	Fluorescence assay of the specificity of human plasma and bovine liver phospholipid transfer proteins. Lipids and Lipid Metabolism, 1985, 835, 124-131.	2.6	38
76	The unique role of apolipoprotein A-I in HDL remodeling and metabolism. Current Opinion in Lipidology, 2006, 17, 209-213.	1.2	38
77	Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 1125-1132.	1.2	36
78	Effects of site-directed mutagenesis on the N-glycosylation sites of human lecithin:cholesterol acyltransferase. Biochemistry, 1993, 32, 8732-8736.	1.2	35
79	Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Atherosclerosis, 1999, 144, 435-442.	0.4	35
80	Scavenger receptor B1 (SR-B1) profoundly excludes high density lipoprotein (HDL) apolipoprotein All as it nibbles HDL-cholesteryl ester. Journal of Biological Chemistry, 2017, 292, 8864-8873.	1.6	35
81	Modulation of angiogenic processes in cultured endothelial cells by low density lipoproteins subfractions from patients with familial hypercholesterolemia. Atherosclerosis, 2006, 186, 448-457.	0.4	34
82	ABCA1-Derived Nascent High-Density Lipoprotein–Apolipoprotein AI and Lipids Metabolically SegregateHighlights. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2260-2270.	1.1	34
83	Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins. Journal of Clinical Lipidology, 2018, 12, 849-856.	0.6	34
84	Short-term vitamin E supplementation before marathon running: a placebo-controlled trial. Nutrition, 1999, 15, 278-283.	1.1	33
85	HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis, 2010, 209, 430-435.	0.4	33
86	Surface Properties of Native Human Plasma Lipoproteins and Lipoprotein Models. Biophysical Journal, 1998, 74, 869-878.	0.2	32
87	N-(2-Naphthyl)-23,24-dinor-5-cholen-22-amin-3β-ol, a fluorescent cholesterol analog. Biochemistry, 1978, 17, 2689-2696.	1.2	31
88	Unsaturated aminophospholipids are preferentially retained by the fast skeletal muscle CaATPase during detergent solubilization. Archives of Biochemistry and Biophysics, 1991, 286, 346-352.	1.4	31
89	The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Contemporary Clinical Trials, 1996, 17, 550-583.	2.0	31
90	ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD Clinical Trial. BMC Medical Genetics, 2011, 12, 89.	2.1	31

#	Article	IF	CITATIONS
91	Structure of Triglyceride-Rich Human Low-Density Lipoproteins According to Cryoelectron Microscopy. Biochemistry, 2003, 42, 14988-14993.	1.2	30
92	Do Genetic Modifiers of High-Density Lipoprotein Cholesterol and Triglyceride Levels Also Modify Their Response to a Lifestyle Intervention in the Setting of Obesity and Type-2 Diabetes Mellitus?. Circulation: Cardiovascular Genetics, 2013, 6, 391-399.	5.1	30
93	Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: Further evidence for a unique form of Metabolic Syndrome in HIV patients. Metabolism: Clinical and Experimental, 2013, 62, 1014-1020.	1.5	29
94	Helical amphipathic moment: application to plasma lipoproteins. FEBS Letters, 1983, 159, 17-23.	1.3	28
95	In vitro binding of synthetic acylated lipid-associating peptides to high-density lipoproteins: effect of hydrophobicity. Biochemistry, 1984, 23, 5337-5342.	1.2	28
96	Apolipoproteins C-I, C-II, and C-III: kinetics of association with model membranes and intermembrane transfer. Biochemistry, 1988, 27, 4500-4505.	1.2	28
97	Mechanism of Association of Human Plasma Apolipoproteins with Dimyristoylphosphatidylcholine. Biophysical Journal, 1982, 37, 177-179.	0.2	27
98	The Structure and Function of Serum Opacity Factor: A Unique Streptococcal Virulence Determinant That Targets High-Density Lipoproteins. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-16.	3.0	27
99	Human plasma high density apolipoprotein A-I: Effect of protein-protein interactions on the spontaneous formation of a lipid-protein recombinant. Biochemical and Biophysical Research Communications, 1981, 99, 466-474.	1.0	26
100	A simplified approach to resonance energy transfer in membranes, lipoproteins and spatially restricted systems. Biophysical Chemistry, 1983, 17, 139-152.	1.5	26
101	Roles of cysteines in human lecithin:cholesterol acyltransferase. Biochemistry, 1993, 32, 3089-3094.	1.2	26
102	Remodeling of Human Plasma Lipoproteins by Detergent Perturbation. Biochemistry, 2005, 44, 9714-9722.	1.2	26
103	Solvent and substituent effects in aromatic carbonyl compounds: the lowest triplet states of xanthone and xanthone-1801. Molecular Physics, 1976, 31, 1393-1406.	0.8	25
104	A review of the unique features of HDL apoproteins. Lipids, 1979, 14, 428-434.	0.7	25
105	Structure and conformational analysis of lipid-associating peptides of apolipoprotein B-100 produced by trypsinolysis. The Protein Journal, 1989, 8, 689-699.	1.1	25
106	Role of Oxysterol Structure on the Microdomain-Induced Microsolubilization of Phospholipid Membranes by Apolipoprotein A-lâ€. Biochemistry, 2005, 44, 14376-14384.	1.2	25
107	Speciated Human High-Density Lipoprotein Protein Proximity Profiles. Biochemistry, 2010, 49, 10656-10665.	1.2	25
108	Apolipoprotein E Mediates Enhanced Plasma High-Density Lipoprotein Cholesterol Clearance by Low-Dose Streptococcal Serum Opacity Factor via Hepatic Low-Density Lipoprotein Receptors In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1834-1841.	1.1	25

#	Article	IF	CITATIONS
109	Detergent-Mediated Phospholipidation of Plasma Lipoproteins Increases HDL Cholesterophilicity and Cholesterol Efflux via SR-Blâ€. Biochemistry, 2006, 45, 11514-11522.	1.2	24
110	Weight Change 2 Years After Termination of the Intensive Lifestyle Intervention in the Look AHEAD Study. Obesity, 2020, 28, 893-901.	1.5	24
111	Raman spectroscopy of the thermal properties of reassembled high-density lipoprotein: apolipoprotein A-I complexes of dimyristoylphosphatidylcholine. Biochemistry, 1981, 20, 656-661.	1.2	23
112	Identification of peptides containing tryptophan, tyrosine, and phenylalanine using photodiode-array spectrophotometry. Analytical Biochemistry, 1985, 145, 67-72.	1.1	23
113	Effect of pressure on phospholipid translocation in lipid bilayers. Journal of the American Chemical Society, 1987, 109, 4759-4760.	6.6	23
114	Impaired Lipoprotein Processing in HIV Patients on Antiretroviral Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1714-1721.	1.1	23
115	The primary structure of apolipoprotein A-I from rabbit high-density lipoprotein. FEBS Journal, 1986, 160, 427-431.	0.2	22
116	Disruption of Human Plasma High-Density Lipoproteins by Streptococcal Serum Opacity Factor Requires Labile Apolipoprotein A-I. Biochemistry, 2009, 48, 1481-1487.	1.2	22
117	Origin of the anomalous phosphorescence of aromatic ketones. Xanthone in 3-methylpentane. Chemical Physics Letters, 1973, 22, 403-405.	1.2	21
118	(1-Pyrenebutyryl)carnitine and 1-pyrenebutyryl coenzyme A: fluorescent probes for lipid metabolite studies in artificial and natural membranes. Biochemistry, 1982, 21, 2990-2996.	1.2	21
119	Hydrolysis of phospholipids by purified milk lipoprotein lipase. Clinica Chimica Acta, 2000, 291, 19-33.	0.5	21
120	Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients. Medicine and Science in Sports and Exercise, 2013, 45, 1043-1050.	0.2	21
121	Replacing Saturated Fat With Unsaturated Fat in Western Diet Reduces Foamy Monocytes and Atherosclerosis in Male <i>Ldlr</i> <sup> <i>–/–</i> </sup> Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 72-85.	1.1	20
122	Spontaneous and plasma factor-mediated transfer of pyrenyl cerebrosides between model and native lipoproteins. Lipids and Lipid Metabolism, 1985, 837, 27-34.	2.6	19
123	Sustained elevations in NEFA induce cyclooxygenase-2 activity and potentiate THP-1 macrophage foam cell formation. Atherosclerosis, 2007, 192, 49-55.	0.4	19
124	Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. Journal of Clinical Lipidology, 2013, 7, 661-670.	0.6	19
125	Synthesis and substituent effects in the nuclear magnetic resonance and mass spectra of dimethyl- and dihaloxanthones. Journal of Organic Chemistry, 1975, 40, 2088-2091.	1.7	18
126	THE ELECTRONIC SPECTROSCOPY OF PYRIMIDINES: THE EFFECT OF COVALENTLY BONDED SULFUR ON THE PHOSPHORESCENCE AND ABSORPTION SPECTRA. Photochemistry and Photobiology, 1978, 27, 625-628.	1.3	18

#	Article	IF	CITATIONS
127	The properties of membranes formed from cyclopentanoid analogues of phosphatidylcholine. Biochimica Et Biophysica Acta - Biomembranes, 1983, 731, 373-377.	1.4	18
128	Thermodynamics of lipid-protein association and the activation of lecithin:Cholesterol acyltransferase by synthetic model apolipopeptides. Lipids and Lipid Metabolism, 1984, 793, 149-156.	2.6	18
129	Effects of fluorophore structure and hydrophobicity on the uptake and metabolism of fluorescent lipid analogs. Chemistry and Physics of Lipids, 1991, 58, 111-119.	1.5	18
130	Free Radical-Induced Alterations in Endothelial Cell Function. Journal of Surgical Research, 1994, 56, 32-36.	0.8	18
131	Cellular Transport of Nonesterified Fatty Acids. Journal of Molecular Neuroscience, 2001, 16, 109-116.	1.1	18
132	Cardiovascular diseases—a major health risk in Asian Indians. Nutrition Research, 2005, 25, 515-533.	1.3	18
133	Heart positive: Design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials, 2006, 27, 518-530.	0.8	18
134	Apolipoprotein Modulation of Streptococcal Serum Opacity Factor Activity against Human Plasma High-Density Lipoproteins. Biochemistry, 2009, 48, 8070-8076.	1.2	18
135	Streptococcal Serum Opacity Factor Increases the Rate of Hepatocyte Uptake of Human Plasma High-Density Lipoprotein Cholesterol. Biochemistry, 2010, 49, 9866-9873.	1.2	18
136	Commentary on Fatty Acid Wars. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, e8-9.	1.1	18
137	Molecular Basis of Fish-Eye Disease in a Patient From Spain. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1382-1391.	1.1	18
138	Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability. Methodist DeBakey Cardiovascular Journal, 2021, 15, 47.	0.5	18
139	Transfer of polycyclic aromatic hydrocarbons between model membranes: Relation to carcinogenicity. Chemico-Biological Interactions, 1983, 44, 237-246.	1.7	17
140	Enhancing reverse cholesterol transport: the case for phosphatidylcholine therapy. Current Opinion in Lipidology, 2005, 16, 265-268.	1.2	17
141	Pyrenedodecanoylcarnitine and pyrenedodecanoyl coenzyme A: kinetics and thermodynamics of their intermembrane transfer. Biochemistry, 1984, 23, 6426-6432.	1.2	15
142	Brain Uptake and Utilization of Fatty Acids, Lipids & Lipoproteins: Recommendations for Future Research. Journal of Molecular Neuroscience, 2007, 33, 146-150.	1.1	15
143	New Insights into the High-Density Lipoprotein Dilemma. Trends in Endocrinology and Metabolism, 2016, 27, 44-53.	3.1	15
144	Direct Measurement of the Structure of Reconstituted High-Density Lipoproteins by Cryo-EM. Biophysical Journal, 2016, 110, 810-816.	0.2	15

#	Article	IF	CITATIONS
145	Chapter 3 Lipid-protein interactions and lipoprotein reassembly. New Comprehensive Biochemistry, 1987, , 95-127.	0.1	14
146	Analysis of the carbohydrate composition of glycoproteins by high-performance liquid chromatography. The Protein Journal, 1990, 9, 31-35.	1.1	14
147	Plasma factors affecting the in vitro conversion of high-density lipoproteins labeled with a non-transferable marker. Lipids and Lipid Metabolism, 1995, 1254, 13-21.	2.6	14
148	High-performance liquid chromatographic analysis of acylated lipids containing pyrene fatty acids. Analytical Biochemistry, 1989, 178, 166-171.	1.1	13
149	Interaction of α-Tocopherol with Model Human High-Density Lipoproteins. Biophysical Journal, 1998, 75, 2923-2931.	0.2	13
150	Mass spectrometric determination of apolipoprotein molecular stoichiometry in reconstituted high density lipoprotein particles. Journal of Lipid Research, 2009, 50, 1229-1236.	2.0	13
151	Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism. Methodist DeBakey Cardiovascular Journal, 2021, 12, 146.	0.5	13
152	Abnormal interaction of the human apolipoprotein A-I variant [Lys107→0] with high density lipoproteins. Biochemical and Biophysical Research Communications, 1985, 133, 856-862.	1.0	12
153	Plasma Factors Required for Human Apolipoprotein A-II Dimerization. Biochemistry, 2005, 44, 471-479.	1.2	12
154	Thermodynamics of lipid–proiein associations: the enthalpy of binding of Apo C-III to synthetic phosphatidylcholines. Canadian Journal of Biochemistry, 1981, 59, 700-708.	1.4	11
155	Serum Opacity Factor Enhances HDLâ€Mediated Cholesterol Efflux, Esterification and Anti Inflammatory Effects. Lipids, 2010, 45, 1117-1126.	0.7	11
156	Solvent and substituent effects in aromatic carbonyl compounds: The triplet state of flavone. Spectrochimica Acta Part A: Molecular Spectroscopy, 1974, 30, 953-959.	0.1	10
157	Thermodynamics of Lipid-Protein Association in Human Plasma Lipoproteins. Biophysical Journal, 1982, 37, 175-177.	0.2	10
158	Structural and Functional Determinants of Human Plasma Phospholipid Transfer Protein Activity As Revealed by Site-Directed Mutagenesis of Charged Amino Acids. Biochemistry, 2003, 42, 4444-4451.	1.2	10
159	Setting the course for apoAll: a port in sight?. Clinical Lipidology, 2013, 8, 551-560.	0.4	10
160	Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study. Diabetes Care, 2021, 44, 67-74.	4.3	10
161	Structure and Dynamics of Human Plasma Lipoproteins. , 1983, , 205-244.		10
162	Association Between Change in Accelerometer-Measured and Self-Reported Physical Activity and Cardiovascular Disease in the Look AHEAD Trial. Diabetes Care, 2022, 45, 742-749.	4.3	10

#	Article	IF	CITATIONS
163	Free Cholesterol Bioavailability and Atherosclerosis. Current Atherosclerosis Reports, 2022, 24, 323-336.	2.0	10
164	Internal heavy atom studies on the triplet state of dimethyl- and dihaloxanthones. The Journal of Physical Chemistry, 1976, 80, 508-511.	2.9	9
165	Fluorescent cholesteryl esters in the core of low density lipoprotein. Biochemical and Biophysical Research Communications, 1982, 105, 674-680.	1.0	9
166	Effect of hydrostatic pressure on the transfer of a fluorescent phosphatidylcholine between apolipoprotein-phospholipid recombinants. Journal of the American Chemical Society, 1984, 106, 3317-3319.	6.6	9
167	Equilibrium of apoproteins between high density lipoprotein and the aqueous phase: Modelling of in vivo metabolism. Journal of Theoretical Biology, 1985, 112, 183-192.	0.8	9
168	The helical hydrophobic moment avoids prolines in phospholipid-binding proteins. Biochemical and Biophysical Research Communications, 1986, 139, 202-208.	1.0	9
169	[23] Thermodynamics of apolipoprotein-phospholipid association. Methods in Enzymology, 1986, 128, 403-413.	0.4	9
170	Disulfide linked dimers of apolipoprotein D in urine. Electrophoresis, 1993, 14, 1086-1087.	1.3	9
171	Mechanism of action of probucol on cholesteryl ester transfer protein (CETP) mRNA in a Chinese hamster ovary cell line that had been stably transfected with a human CETP gene. Lipids and Lipid Metabolism, 1998, 1393, 153-160.	2.6	9
172	High Free Cholesterol Bioavailability Drives the Tissue Pathologies in Scarb1 â^'/â^' Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e453-e467.	1.1	9
173	Reversible folding reactions of human apolipoprotein A-I: pressure and guanidinium chloride effects. Lipids and Lipid Metabolism, 1985, 836, 215-221.	2.6	8
174	Spectroscopic studies of the tyrosine residues of human plasma apolipoprotein A-II. BBA - Proteins and Proteomics, 1989, 999, 111-120.	2.1	8
175	Effects of site-directed mutagenesis on the serine residues of human lecithin: Cholesterol acyltransferase. Lipids, 1994, 29, 803-809.	0.7	8
176	Role of cysteine residues in human plasma phospholipid transfer protein. The Protein Journal, 1999, 18, 193-198.	1.1	8
177	Cholesterol Determines and Limits rHDL Formation from Human Plasma Apolipoprotein A-II and Phospholipid Membranes. Biochemistry, 2012, 51, 8627-8635.	1.2	8
178	Relationship of ethnicity and CD4 Count with glucose metabolism among HIV patients on Highly-Active Antiretroviral Therapy (HAART). BMC Endocrine Disorders, 2013, 13, 13.	0.9	8
179	Alcohol: A Nutrient with Multiple Salutary Effects. Nutrients, 2015, 7, 1992-2000.	1.7	8
180	Changes in regional body composition over 8 years in a randomized lifestyle trial: The look AHEAD study. Obesity, 2016, 24, 1899-1905.	1.5	8

#	Article	IF	CITATIONS
181	History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial. Obesity, 2020, 28, 247-258.	1.5	8
182	Cholesterol: Can't Live With It, Can't Live Without It. Methodist DeBakey Cardiovascular Journal, 2021, 15, 9.	0.5	8
183	Kinetics and mechanism of transfer of synthetic model apolipoproteins. Biochemistry, 1988, 27, 7881-7886.	1.2	7
184	Regulation of Acyl-Coenzyme A:Cholesterol Acyltransferase (ACAT) Synthesis, Degradation, and Translocation by High-Density Lipoprotein 2 at a Low Concentration. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2636-2642.	1.1	7
185	Free Cholesterol Determines Reassembled High-Density Lipoprotein Phospholipid Phase Structure and Stability. Biochemistry, 2013, 52, 4324-4330.	1.2	7
186	Commentary on SSO and other putative inhibitors of FA transport across membranes by CD36 disrupt intracellular metabolism, but do not affect fatty acid translocation. Journal of Lipid Research, 2020, 61, 595-597.	2.0	7
187	The Alcohol–High-Density Lipoprotein Athero-Protective Axis. Biomolecules, 2020, 10, 987.	1.8	7
188	In vitro transfer of phosphatidylcholines and their ether analogs by a human and rat plasma exchange factor. Biochemical and Biophysical Research Communications, 1984, 119, 452-457.	1.0	6
189	Phospholipids Chiral at Phosphorus. 13. Stereochemical Comparison of Phospholipase A <sub>2</sub> , Lecithin-Cholesterol Acyl Transferase, and Platelet-Activating Factor. Phosphorous and Sulfur and the Related Elements, 1987, 30, 601-604.	0.2	6
190	Kinetics of tryptic hydrolysis as a probe of the structure of human plasma apolipoprotein A-II. BBA - Proteins and Proteomics, 1989, 999, 121-127.	2.1	6
191	Cyclopentanoid analogs of dipalmitoyl phosphatidic acid: effect of backbone geometry on thermotropic properties. Chemistry and Physics of Lipids, 1990, 55, 231-243.	1.5	6
192	Efficient Nuclear Delivery of Antisense Oligodeoxynucleotides and Selective Inhibition of CETP Expression by Apo E Peptide in a Human CETP–Stably Transfected CHO Cell Line. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2207-2213.	1.1	6
193	Properties of the products formed by the activity of serum opacity factor against human plasma high-density lipoproteins. Chemistry and Physics of Lipids, 2008, 156, 45-51.	1.5	6
194	Lipids and Cardiovascular Disease: Putting It All Together. Methodist DeBakey Cardiovascular Journal, 2021, 15, 5.	0.5	6
195	Alcohol: Lipid metabolism and cardioprotection. Current Atherosclerosis Reports, 2002, 4, 107-112.	2.0	5
196	N-Glycosylation is Required for Secretion-Competent Human Plasma Phospholipid Transfer Protein. Protein Journal, 2006, 25, 167-173.	0.7	5
197	Apolipoprotein Al Deficiency Inhibits Serum Opacity Factor Activity against Plasma High Density Lipoprotein via a Stabilization Mechanism. Biochemistry, 2015, 54, 2295-2302.	1.2	5
198	Neo High-Density Lipoprotein Produced by the Streptococcal Serum Opacity Factor Activity against Human High-Density Lipoproteins Is Hepatically Removed via Dual Mechanisms. Biochemistry, 2016, 55, 5845-5853.	1.2	5

1

#	Article	IF	CITATIONS
199	Streptococcal serum opacity factor promotes cholesterol ester metabolism and bile acid secretion in vitro and in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 196-204.	1.2	5
200	High-Density Lipoprotein Processing and Premature Cardiovascular Disease. Methodist DeBakey Cardiovascular Journal, 2021, 11, 181.	0.5	4
201	Dietary Alcohol and Fat Differentially Affect Plasma Cholesteryl Ester Transfer Activity and Triglycerides in Normo―and Hypertriglyceridemic Subjects. Lipids, 2020, 55, 299-307.	0.7	4
202	Physico-chemical and physiological determinants of lipo-nanoparticle stability. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 33, 102361.	1.7	4
203	Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlrâ^'/â^' Mice. Cells, 2022, 11, 1795.	1.8	4
204	THE SPECTROSCOPY AND PHOTOCHEMISTRY OF ENAMINONITRILES INCLUDING THE SYNTHESIS AND IDENTIFICATION OF CIS-Î <sup>2</sup> -AMINOACRYLONITRILE. Photochemistry and Photobiology, 1976, 24, 217-222.	1.3	3
205	Mechanism of Cellular Phospholipid Efflux. Journal of Surgical Research, 1993, 55, 548-552.	0.8	3
206	Effects of visceral adipose tissue reduction on CVD risk factors independent of weight loss: The Look AHEAD study. Endocrine Research, 2017, 42, 86-95.	0.6	3
207	Highly conserved amino acid residues in apolipoprotein A1 discordantly induce high density lipoprotein assembly in vitro and in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158794.	1.2	3
208	Control of Spontaneous Lipid and Protein Transport. Advances in Experimental Medicine and Biology, 1988, 243, 173-177.	0.8	3
209	Photo-oxidation in the synthesis of170 and180 labelled compounds: Synthesis of xanthone-1801. Journal of Labelled Compounds, 1974, 10, 413-417.	0.3	2
210	Physical aspects of fatty acid transport between and through biological membranes. Advances in Molecular and Cell Biology, 2003, 33, 153-172.	0.1	2
211	Rethinking apolipoprotein A-II in lipid metabolism. American Journal of Clinical Nutrition, 2018, 108, 4-5.	2.2	2
212	Vulnerable Atherosclerotic Plaque Imaging by Smallâ€Molecule Highâ€Affinity Positron Emission Tomography Radiopharmaceutical. Advanced Therapeutics, 2019, 2, 1900005.	1.6	2
213	Human Plasma Lipoprotein Metabolism. , 2009, , 1-10.		2
214	Impurity phosphorescence in methylene anthrone. Journal of Chemical Physics, 1973, 58, 3116.	1.2	1
215	A Metabolic Model for the Hypolipidemic and Antiatherogenic Effects of N-3 Fatty Acids: Effect of Omacor on Plasma Lipids. Medical Science Symposia Series, 1996, , 675-680.	0.0	1

Plasma Lipoproteins: Fluorescence as a Probe of Structure and Dynamics. , 1983, , 163-202.

#	Article	IF	CITATIONS
217	Prevention and Treatment of Atherosclerotic Vascular Disease: Hypolipidemic Agents. , 2015, , 589-611.		0
218	Acylation of lysine residues in human plasma high density lipoprotein increases stability and plasma clearance in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1787-1795.	1.2	0
219	Structural Stability of Streptococcal Serum Opacity Factor. Protein Journal, 2017, 36, 196-201.	0.7	0
220	Abstract P220: The Effect of Diet-Induced Weight Loss on HDL Functionality in Individuals with Metabolic Syndrome: Investigating Alteration of the Initial Step in Reverse Cholesterol Transport as a Function of Plasma Lipoprotein Composition. Circulation, 2012, 125, .	1.6	0
221	Abstract 46: Cholesteryl Ester Transfer Protein Interactions with Lipoproteins: Insights into Mechanisms by Electron Microscopy and Molecular Dynamics Simulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, .	1.1	0
222	The Role of Hydrophobicity in the Structure of the Human Plasma Lipoproteins. , 1985, 183, 85-97.		0
223	Dyslipidemia, Diabetes, and Cell Adhesion Molecules. Medical Science Symposia Series, 1998, , 191-198.	0.0	0
224	Abstract 105: Free Cholesterol Determines the Phospholipid Domain Size and Stability of rHDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, .	1.1	0